Meribank Biotech
CompanyTaiwan
Meribank Biotech develops one asset, in phase 1 (UMC119-06-05 in pathologic processes). Mostly cell therapy acting on inflammation and stem cell maintenance; based in Taiwan.
- 1
- Asset
- Furthest stage
- Phase 1
- 1
- Trial
- 0
- Signals
Pipeline
1Allogeneic umbilical cord mesenchymal stem cells administered to mitigate frailty syndrome.
Phase 1, Cell therapy, Inflammation, Stem cell maintenance, pathologic processes
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials1
- Similar companies6